Compare United States Copper Index Fund (CPER) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Copper Index Fund vs Citius Pharmaceuticals Inc — how do they compare? United States Copper Index Fund trades at $40.22, while Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M). The key difference: United States Copper Index Fund is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CPER | CTXR | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $40.85 | $1.82 |
52-Week Low | $27.57 | $0.48 |
Market Cap | — | $18.73M |
Enterprise Value | — | $14.95M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPER, the United States Copper Index Fund, trades at $39.9, down 2.11% today, amid a broader bullish technical signal driven by moving averages. Recent news highlights record copper prices fueled by supply disruptions and strong demand from electrification and AI infrastructure. Key support sits at $39, with resistance at $41. Financial ratios are not applicable as this is an ETF tracking copper futures.
The outlook for CPER is positive, supported by structural copper demand trends, but carries risks from potential supply normalization and commodity price volatility. Investors gain exposure to copper's price movements without direct company fundamentals, making it a pure play on industrial metal trends influenced by global economic conditions.
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About United States Copper Index Fund
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
